Cardan Capital Partners’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Cardan Capital Partners’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-5,762	Closed	-$310K	–	204
2017 Q4	$310K	Buy	5,762 +18	+0.3%	+$985	0.06%	104
2017 Q3	$328K	Buy	5,744 +8	+0.1%	+$469	0.07%	94
2017 Q2	$345K	Sell	5,736 -112	-2%	-$6.38K	0.07%	94
2017 Q1	$318K	Buy	+5,848	New	+$288K	0.07%	95

Other funds holding BIVV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Cardan Capital Partners's BIVV Position: Q1 2018 in Review

Cardan Capital Partners sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 5,762 shares — an estimated $310K sold.

Cardan Capital Partners first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $345K in Q2 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

Cardan Capital Partners reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Cardan Capital Partners sold 5,762 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $310K.
Cardan Capital Partners first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
Cardan Capital Partners's Bioverativ Inc. Common Stock position peaked at $345K in Q2 2017.
2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Cardan Capital Partners's 13F filing for Q1 2018, filed 12 Apr 2018.